Oncolytics Biotech (ONCY) Accounts Payables (2009 - 2026)
Oncolytics Biotech (ONCY) posted quarterly Accounts Payables of $3.5 million for Q4 2025, up 2.15% year-over-year from $3.4 million in Q4 2024, and down 32.82% quarter-over-quarter from $5.2 million in Q3 2025.
Oncolytics Biotech (ONCY) Accounts Payables (2009 - 2026) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Accounts Payables for 17 consecutive years, with $3.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Accounts Payables rose 2.15% year-over-year to $3.5 million; the TTM figure through Dec 2025 stood at $3.5 million (up 2.15% YoY), while the FY2025 annual figure was $3.5 million, up 363.49% from the prior year.
- Accounts Payables retreated to $3.5 million in Q4 2025 per ONCY's latest filing, from $5.2 million in the prior quarter.
- Across five years, Accounts Payables topped out at $5.2 million in Q3 2025 and bottomed at $1.5 million in Q1 2021.
- Historically, Accounts Payables has averaged $2.6 million across 5 years, with a median of $2.6 million in 2022.
- Annual changes were most pronounced in 2021 — Accounts Payables sank 45.44% — and 2025, when it surged 112.39%.
- Oncolytics Biotech's Accounts Payables stood at $1.6 million in 2021, then jumped by 70.5% to $2.7 million in 2022, then slipped by 2.42% to $2.6 million in 2023, then surged by 30.74% to $3.4 million in 2024, then increased by 2.15% to $3.5 million in 2025.
- Business Quant data shows ONCY's Accounts Payables at $3.5 million in Q4 2025, $5.2 million in Q3 2025, and $3.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Oncolytics Biotech | 101.16 Mn | 101.16 Mn | - | 3.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.41 Mn |
| Dec 31, 2025 | 3.50 Mn |
| Sep 30, 2025 | 5.22 Mn |
| Jun 30, 2025 | 3.81 Mn |
| Mar 31, 2025 | 3.45 Mn |
| Dec 31, 2024 | 3.43 Mn |
| Sep 30, 2024 | 2.46 Mn |
| Jun 30, 2024 | 3.40 Mn |
| Mar 31, 2024 | 2.68 Mn |
| Dec 31, 2023 | 2.62 Mn |
| Sep 30, 2023 | 3.38 Mn |
| Jun 30, 2023 | 1.76 Mn |
| Mar 31, 2023 | 1.65 Mn |
| Dec 31, 2022 | 2.69 Mn |
| Sep 30, 2022 | 2.55 Mn |
| Jun 30, 2022 | 1.71 Mn |
| Mar 31, 2022 | 1.62 Mn |
| Dec 31, 2021 | 1.58 Mn |
| Sep 30, 2021 | 1.85 Mn |
| Jun 30, 2021 | 1.78 Mn |